Globo-H

03/13/2001 - "Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial."
01/30/2015 - "Quantitative analysis of GSLs revealed both Fuc-LacCer and Globo-H increased in breast cancer tissues. "
12/01/2014 - "Breast cancer cells expressing high levels of GHCer displayed relatively greater tumorigenicity and angiogenesis compared with cells expressing low levels of Globo-H. "
08/19/2008 - "Globo H is a member of this family, which is highly expressed on breast cancer cells. "
08/19/2008 - "Flow cytometry revealed Globo H expression in 25/41 breast cancer specimens (61.0%). "

10/01/2016 - "While GD2-targeted immunotherapy of neuroblastoma represents the first antiglycan monoclonal antibody to obtain FDA approval for standard medical care, Globo H-targeted immunotherapy of breast cancer has generated promising results in the ongoing multinational clinical trials. "
01/01/2001 - "Well-documented examples of such TACAs are: (i) H/Le(y)/Le(a) in primary non-small cell lung carcinoma; (ii) sialyl-Le(x) (SLe(x)) and sialyl-Le(a) (SLe(a)) in various types of cancer; (iii) Tn and sialyl-Tn in colorectal, lung, breast, and many other cancers; (iv) GM2, GD2, and GD3 gangliosides in neuroectodermal tumors (melanoma and neuroblastoma); (v) globo-H in breast, ovarian, and prostate cancer; (vi) disialylgalactosylgloboside in renal cell carcinoma. "

01/01/2023 - "A phase II cohort-expansion study is now enrolling patients with pancreatic, colorectal, and other cancers expressing high levels of Globo H."
06/06/2023 - "The expression of SSEA3, Globo H, and SSEA4 in tumor tissues obtained from 382 patients with resectable HCC was examined by immunohistochemistry staining. "
01/01/2023 - "Patients with tumors exhibiting higher Globo H expression (H-score ≥ 80) demonstrated significantly shorter disease-free survival (DFS) and overall survival (OS) (P = 0.0001 and P = 0.0004, respectively). "
01/01/2023 - "This was the highest frequency among Globo H expressing cancers. "
01/01/2023 - "Globo H in tumor specimens was detected by immunohistochemistry (IHC) and mass spectrometry analysis. "

12/03/2014 - "Globo H-based therapeutic cancer vaccines have been tested in clinical trials for the treatment of late stage breast, ovarian, and prostate cancers. "
05/11/1999 - "Globo H is one of several candidate antigens present on prostate cancer cells that can serve as targets for immune recognition and treatment strategies. "
01/01/2001 - "Examples are STn for suppression of breast cancer, GM2 and GD3 for melanoma, and globo-H for prostate cancer. "
02/15/1999 - "A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle."
03/01/2002 - "Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alpha1,2-L-fucosyltransferase."

02/10/2017 - "Our data demonstrate that human plasma-derived antibodies to Globo H as well as the presence of the antigen might be considered as therapeutic option in ovarian cancer."
02/10/2017 - "Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients."
01/03/2006 - "Reported here is the synthesis of the cancer antigen Globo H hexasaccharide, an epitope found on the cell surface of breast, prostate, and ovarian cancers, and its truncated sequences by using the programmable one-pot synthesis strategy. "
02/10/2017 - "The incubation of plasma-derived anti-glycan antibodies with chemically synthesized (presented on fluorescence microspheres) and native Globo H (expressed on Globo H-positive cell lines) revealed strong reactivity of naturally occurring human anti-Globo H antibodies towards its antigen expressed on ovarian cancer cells. "
02/10/2017 - "Here we investigated the levels of naturally occurring anti-glycan antibodies to Globo H in blood plasma obtained from high-grade serous ovarian cancer patients (SOC) and women without gynaecological malignancies (control) using suspension glycan array technology employing chemically synthesized glycans as antibody targets. "